Cell-free DNA comparative analysis of the genomic landscape of first-line hormone receptor-positive metastatic breast cancer from the US and China.
Circulating tumor DNA
HR-positive advanced breast cancer
Next-generation sequencing
Journal
Breast cancer research and treatment
ISSN: 1573-7217
Titre abrégé: Breast Cancer Res Treat
Pays: Netherlands
ID NLM: 8111104
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
received:
26
04
2021
accepted:
20
08
2021
pubmed:
3
9
2021
medline:
3
11
2021
entrez:
2
9
2021
Statut:
ppublish
Résumé
Meaningful comparison of mutational landscapes across ethnic groups requires the use of standardized platform technology. We have used a harmonized NGS-based liquid biopsy assay to explore the differential genomic landscape of patients with initially hormone receptor-positive (HR+), HER2-negative MBC of first line metastasis or primary Stage IV at diagnosis from the United States (US) and China (CN). Plasma circulating tumor DNA (ctDNA) from 27 US patients and 65 CN patients was sequenced using the harmonized CLIA-certified, 152-gene PredicineCare™ liquid biopsy assay. Kaplan-Meier survival analysis was performed to analyze the correlation between genomic alterations and progression-free survival (PFS), and p-values were calculated using the log-rank test. All patients in the CN cohort received chemotherapy and/or hormonal therapy, while 85.2% (23/27) patients in the US cohort received hormonal therapy plus CDK4/6 inhibitors. Mutations were detected in 23 of 27 (85%) US patients and 54 of 65 (83%) CN patients. The prevalence of AKT1 (P = 0.008) and CDH1 (P = 0.021) alterations were both higher in the US vs. CN cohort. In addition, FGFR1 amplification were more frequent in the CN vs. US cohort (P = 0.048). PTEN deletions (P = 0.03) and ESR1 alterations (P = 0.02) were associated with shorter PFS in the CN cohort, neither of these associations were observed in the US cohort. Interestingly, a reduced association between PTEN deletion and PFS was observed in patients receiving CDK4/6 inhibitor treatment. The differential prevalence of ctDNA-based alterations such as FGFR1, AKT1, and CDH1 was observed in initially HR+/HER2- MBC patients in the US vs. CN. In addition, the association of PTEN deletions with shorter PFS was found in the CN but not the US cohort. The differential genomic landscapes across the two ethnic groups may reflect biologic differences and clinical implications.
Identifiants
pubmed: 34471951
doi: 10.1007/s10549-021-06370-w
pii: 10.1007/s10549-021-06370-w
pmc: PMC8558197
doi:
Substances chimiques
Biomarkers, Tumor
0
Cell-Free Nucleic Acids
0
Circulating Tumor DNA
0
Hormones
0
Receptor, ErbB-2
EC 2.7.10.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
213-226Subventions
Organisme : Beijing Natural Science Foundation
ID : 7212011
Informations de copyright
© 2021. The Author(s).
Références
Crit Rev Oncol Hematol. 2020 Jan;145:102856
pubmed: 31884205
Cancer. 2017 May 15;123(10):1721-1730
pubmed: 28085182
Cancer Cell. 2019 Mar 18;35(3):428-440.e5
pubmed: 30853353
J Clin Oncol. 2020 Apr 20;38(12):1346-1366
pubmed: 31928404
Ann Oncol. 2017 Nov 1;28(11):2866-2873
pubmed: 28945887
JAMA Oncol. 2017 Sep 1;3(9):1190-1196
pubmed: 28418444
Am J Cancer Res. 2018 Sep 01;8(9):1873-1886
pubmed: 30323979
Cancer Med. 2017 Mar;6(3):547-554
pubmed: 28135048
Clin Cancer Res. 2020 Jun 1;26(11):2565-2572
pubmed: 32019858
Front Oncol. 2020 Dec 15;10:587671
pubmed: 33384956
Clin Cancer Res. 2017 Jul 1;23(13):3251-3262
pubmed: 28351928
Nat Commun. 2018 Apr 10;9(1):1357
pubmed: 29636477
Breast Cancer Res. 2019 Dec 19;21(1):149
pubmed: 31856868
N Engl J Med. 2019 May 16;380(20):1929-1940
pubmed: 31091374
Am J Epidemiol. 2009 May 15;169(10):1251-9
pubmed: 19318616
Nature. 2019 May;569(7757):560-564
pubmed: 31118521
Nat Cancer. 2020 Apr;1(4):382-393
pubmed: 32864625
Nat Commun. 2016 May 13;7:11579
pubmed: 27174596
J Ethnopharmacol. 2009 Mar 18;122(2):234-9
pubmed: 19330917
Cancer Med. 2019 Sep;8(12):5544-5553
pubmed: 31385461
Cancer Res Treat. 2019 Jan;51(1):128-140
pubmed: 29540052
Curr Drug Targets. 2014 Jan;15(1):65-79
pubmed: 24387334
Cell Mol Life Sci. 2020 Feb;77(3):497-509
pubmed: 31254045
Cancer Discov. 2018 Nov;8(11):1390-1403
pubmed: 30206110
Cancer Med. 2015 Jul;4(7):1016-30
pubmed: 25787708
Asian Pac J Cancer Prev. 2014;15(22):10021-5
pubmed: 25520063
Anticancer Res. 2019 Oct;39(10):5653-5662
pubmed: 31570463
Br J Cancer. 2017 Mar 14;116(6):726-730
pubmed: 28183140
Annu Rev Med. 2011;62:233-47
pubmed: 20887199
Breast Cancer Res Treat. 2019 Apr;174(3):639-647
pubmed: 30607632
Biomed Res Int. 2019 Nov 5;2019:2183510
pubmed: 31781598
Breast Cancer Res. 2019 Dec 4;21(1):137
pubmed: 31801599
JAMA Oncol. 2016 Oct 1;2(10):1310-1315
pubmed: 27532364
Thorac Cancer. 2019 Apr;10(4):807-814
pubmed: 30793491
Adv Clin Chem. 2020;97:171-223
pubmed: 32448434
Clin Cancer Res. 2007 Oct 15;13(20):6064-9
pubmed: 17947469
Ann Oncol. 2019 Dec 1;30(Suppl_10):x3-x11
pubmed: 31859348
Cancer Manag Res. 2018 Aug 14;10:2573-2580
pubmed: 30147360
Ann Transl Med. 2019 Apr;7(8):179
pubmed: 31168460